莫德纳将向台湾供应500万剂新冠疫苗 料年中开始交付
《路透》报道,美国药厂莫德纳(MRNA.US)表示,已与台湾及哥伦比亚达成新冠疫苗供应协议,预计将於今年年中开始交付。该药厂将为台湾提供500万剂疫苗,及为哥伦比亚提供1,000万剂疫苗。
莫德纳疫苗目前尚未获得台湾和哥伦比亚批准使用,公司在声明中表示,将与监管机构合作,期望在疫苗交付前获批。
台湾於去年底表示,已同意购买近2,000万剂疫苗,包括从阿斯利康(AZN.US)购买1,000万剂,首批疫苗将在3月开始送达。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.